641 related articles for article (PubMed ID: 8941648)
1. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
2. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
3. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
5. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
[TBL] [Abstract][Full Text] [Related]
7. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
[TBL] [Abstract][Full Text] [Related]
8. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
9. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
10. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
[TBL] [Abstract][Full Text] [Related]
12. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
[TBL] [Abstract][Full Text] [Related]
15. Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Infect Immun; 2000 Oct; 68(10):5749-55. PubMed ID: 10992481
[TBL] [Abstract][Full Text] [Related]
16. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
Baker CJ; Rench MA; McInnes P
Vaccine; 2003 Jul; 21(24):3468-72. PubMed ID: 12850362
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
18. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
[TBL] [Abstract][Full Text] [Related]
19. Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk.
Lagergård T; Thiringer K; Wassén L; Schneerson R; Trollfors B
Eur J Pediatr; 1992 Feb; 151(2):98-102. PubMed ID: 1537371
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
